A study published in the journal Science and coordinated by researchers of IDIBAPS and the UB describes a new immune defence mechanism unknown until1
Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Ho1
Reveal Genomics’ first goal will be to develop diagnostic tools based on complex genomic data for patients with advanced breast cancer.
An AI model based on information from more than three thousand clinical reports generated by the Hospital Clínic during the acute phase of the pandem1
The pandemic and lockdown caused by COVID-19 have increased symptoms of anxiety and depression in the population. However, according to a major surve1
Hospital Clínic de Barcelona-IDIBAPS and Cellnex have today signed an agreement to launch a multicentre research project that will allow better under1
Researchers of IDIBAPS have participated in an interdisciplinary research study of the UB in which there have been identified two potential candidate1
Hospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating h1
Researchers from the Respiratory biophysics and bioengineering IDIBAPS research group, the Biophysics and Bioengineering Unit of the UB and the CIBER1
Uveitis is a disease that causes inflammation of the tissues inside the eye. More specifically, non-infectious uveitis (NIU) causes 20% of cases of b1